Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Deffered Revenue (2016 - 2017)

Historic Non-Current Deffered Revenue for Arcadia Biosciences (RKDA) over the last 4 years, with Q4 2017 value amounting to $2.0 million.

  • Arcadia Biosciences' Non-Current Deffered Revenue fell 3467.95% to $2.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $2.0 million, marking a year-over-year decrease of 3467.95%. This contributed to the annual value of $2.0 million for FY2017, which is 3467.95% down from last year.
  • According to the latest figures from Q4 2017, Arcadia Biosciences' Non-Current Deffered Revenue is $2.0 million, which was down 3467.95% from $2.8 million recorded in Q3 2017.
  • Arcadia Biosciences' 5-year Non-Current Deffered Revenue high stood at $3.6 million for Q4 2014, and its period low was $2.0 million during Q4 2017.
  • For the 4-year period, Arcadia Biosciences' Non-Current Deffered Revenue averaged around $2.8 million, with its median value being $2.8 million (2017).
  • Examining YoY changes over the last 5 years, Arcadia Biosciences' Non-Current Deffered Revenue showed a top increase of 2843.99% in 2017 and a maximum decrease of 3467.95% in 2017.
  • Arcadia Biosciences' Non-Current Deffered Revenue (Quarter) stood at $3.6 million in 2014, then dropped by 27.48% to $2.6 million in 2015, then grew by 18.32% to $3.1 million in 2016, then plummeted by 34.68% to $2.0 million in 2017.
  • Its last three reported values are $2.0 million in Q4 2017, $2.8 million for Q3 2017, and $2.9 million during Q2 2017.